Reference:
1. Walker C, Badawy SZ. Vaginal Atrophy following Long-Term Depot Medroxyprogesterone Acetate Use: A Case Report. Case Rep Obstet Gynecol. 2013;2013:835316.
2. Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab. 2010;95(11):4909-4916.
3. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004;70(4):269-275.
4. Dinh A, Sriprasert I, Williams AR, Archer DF. A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women. Contraception. 2015;91(5):360-367.
5. Liang AP, Levenson AG, Layde PM, et al. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA. 1983;249(21):2909-2912.
6. Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. 2016;214(1):31-44.
Keywords:
provera, medroxy-progesterone, ประจำเดือนมาไม่ปกติ